Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Neoplasms 1Neoplasm Metastasis 1Meningeal Carcinomatosis 1Hormone Refractory Prostate Cancer 1Head and Neck Neoplasms 1Glioblastoma 1Colorectal Neoplasms 1Colonic Neoplasms 1Central Nervous System Neoplasms 1Breast Neoplasms, Male 1Breast Neoplasms 1Brain Neoplasms 1

Interventions

Docetaxel 3Prednisone 2sargramostim 1epothilone B 1cabazitaxel 1Sunitinib 1PE regimen 1Interleukin-2 1Injections 1Everolimus 1Etoposide 1Cyclophosphamide 1Cisplatin 1Carboplatin 14-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Hormone Refractory Prostate Cancer × epothilone B × Clear all
NCT00407251 2010-11-05

Study of Patupilone in Prostate Cancer Patients Who Progress After Hormone Therapy and Docetaxel Chemotherapy

British Columbia Cancer Agency

Phase 2 Completed
73 enrolled
Genitourinary

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡